Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice

Vaccine

Volumn 27, Issue 31, 2009, Pages 4219-4224

  Quintilio, Wagner ^a   Kubrusly, Flavia S ^a   Iourtov, Dmitri ^a   Miyaki, Cosue ^a   Sakauchi, Maria Aparecida ^a   Lúcio, Fernanda ^a   de Cássia Dias, Sandra ^a   Takata, Celia S ^a   Miyaji, Eliane N ^a   Higashi, Hisako G ^a   Leite, Luciana C C ^a   Raw, Isaias ^a  

^a INSTITUTO BUTANTAN   (Brazil)

Author keywords

Adjuvant; Influenza vaccine; MPLA

Indexed keywords

ALUMINUM HYDROXIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INACTIVATED VACCINE; INFLUENZA VACCINE; INTERLEUKIN 4; PHOSPHORYL LIPID A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HEMAGGLUTINATION INHIBITION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SPLEEN CELL; TH2 CELL; VIRION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, VIRAL; BORDETELLA PERTUSSIS; HEMAGGLUTINATION INHIBITION TESTS; IMMUNOGLOBULIN G; INFLUENZA VACCINES; INTERFERON-GAMMA; INTERLEUKIN-4; LIPID A; MICE; MICE, INBRED BALB C; VACCINES, SUBUNIT;

EID: 67349085088     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.047     Document Type: Article

References (28)

1. Monto A.S. Epidemiology of influenza. Vaccine 26 Suppl. 4 (2008) D45-D48
2. Monto A.S., and Whitley R.J. Seasonal and pandemic influenza: a 2007 update on challenges and solutions. Clin Infect Dis 46 7 (2008) 1024-1031
3. Hampson A.W. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singapore 37 6 (2008) 510-517
4. WHO manual on animal influenza-diagnosis and surveillance WHO/CDS/CSR/NCS/2002.5 http://www.who.int/vaccine_research/diseases/influenza/WHO_manual_on_animal-diagnosis_and_surveillance_2002_5.pdf.
5. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 13 (2006) 1343-1351
6. Davenport F.M., Hennessy A.V., and Askin F.B. Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man. J Immunol 100 5 (1968) 1139-1140
7. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 9523 (2006) 1657-1664
8. El Sahly H.M., and Keitel W.A. Pandemic H5N1 influenza vaccine development: an update. Exp Rev Vaccines 7 2 (2008) 241-247
9. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 9587 (2007) 580-589
10. Ulrich J.T. MPL Immunostimulant: adjuvant formulations (2000), Humana Press, Totowa, NJ pp. 273-282
11. Qureshi N., Mascagni P., Ribi E., and Takayama K. Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. J Biol Chem 260 9 (1985) 5271-5278
12. Schwarz T.F. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines 7 10 (2008) 1465-1473
13. Kundi M. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 6 2 (2007) 133-140
14. Fitzgerald K.A., and Golenbock D.T. Immunology. The shape of things to come. Science 316 5831 (2007) 1574-1576
15. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., and Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316 5831 (2007) 1628-1632
16. Visintin A., Halmen K.A., Latz E., Monks B.G., and Golenbock D.T. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol 175 10 (2005) 6465-6472
17. Raw I, Kubrusly FS, et al. Method to obtain monophosphoryl lipid A as a by-product of cellular pertussis vaccine production. WO/2008/134830, publication date Nov. 13, 2008.
18. Caroff M., Deprun C., Richards J.C., and Karibian D. Structural characterization of the lipid A of Bordetella pertussis 1414 endotoxin. J Bacteriol 176 16 (1994) 5156-5159
19. Geurtsen J. Improving pertussis vaccines by lipopolycaccharide engineering. Ipskamp, Enschede; 2007.
20. Karkhanis Y.D., Zeltner J.Y., Jackson J.J., and Carlo D.J. A new and improved microassay to determine 2-keto-3-deoxyoctonate in lipopolysaccharide of Gram-negative bacteria. Anal Biochem 85 2 (1978) 595-601
21. Rouser G., Fkeischer S., and Yamamoto A. Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5 5 (1970) 494-496
22. Nascimento I.P., Dias W.O., Mazzantini R.P., Miyaji E.N., Gamberini M., Quintilio W., et al. Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice. Infect Immun 68 9 (2000) 4877-4883
23. Couch R.B., Winokur P., Brady R., Belshe R., Chen W.H., Cate T.R., et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25 44 (2007) 7656-7663
24. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13 9 (2006) 981-990
25. Fazekas G., Rosenwirth B., Dukor P., Gergely J., and Rajnavolgyi E. IgG isotype distribution of local and systemic immune responses induced by influenza virus infection. Eur J Immunol 24 12 (1994) 3063-3067
26. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 4 (2008) 552-561
27. Arulanandam B.P., Mittler J.N., Lee W.T., O'Toole M., and Metzger D.W. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J Immunol 164 7 (2000) 3698-3704
28. Moran T.M., Park H., Fernandez-Sesma A., and Schulman J.L. Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis 180 3 (1999) 579-585